胎儿腹围生长轨迹、孕早期母亲代谢物特征与儿童期生长及肥胖的关联:前瞻性观察性跨国INTERBIO-21st胎儿研究
在巴西、肯尼亚、巴基斯坦、南非、泰国和英国六个国家开展的前瞻性观察性INTERBIO-21st胎儿研究中,纳入3598名孕妇并随访其婴儿至2岁。研究识别出四种胎儿腹围生长轨迹,其与孕早期母亲代谢物特征、胎儿胎盘血流及幼儿期生长、肥胖、视力和神经发育结局相关;与生长迟缓表型相关的代谢物比值比接近1.5,与早期加速生长表型相关的代谢物比值比接近0.6,均具统计学显著性。作者认为孕早期脂质生物学可作为至2岁生长、肥胖、视力和神经发育模式的指标,可能有助于更早识别有肥胖风险的婴儿。
要点
- 研究识别出四种胎儿腹围生长轨迹:生长迟缓、早期加速生长、晚期加速生长和居中生长跟踪,在20-25周孕龄窗口内加速或减速。
- 与生长迟缓表型相关的母亲代谢物比值比接近1.5(具统计学显著性),与早期加速生长表型相关的代谢物比值比接近0.6(具统计学显著性)。
- 母亲代谢物特征包括5-羟基二十碳四烯酸和11种与氧化脂质或饱和脂肪酸侧链相关的磷脂酰胆碱;杀菌剂百菌清在早期加速生长表型组中高度丰富。
核心结论
- 孕早期与胎儿腹围生长轨迹相关的脂质生物学是至2岁生长、肥胖、视力和神经发育模式的指标。
- 研究结果可能有助于更早识别有肥胖风险的婴儿。
研究设计与样本
- 前瞻性、跨国、观察性INTERBIO-21st胎儿研究,在巴西佩洛塔斯、肯尼亚内罗毕、巴基斯坦卡拉奇、南非索韦托、泰国湄索和英国牛津的产科单位开展。
- 纳入年龄≥18岁、BMI低于35 kg/m²、自然受孕、单胎妊娠且在孕14周前开始产前保健的孕妇。
- 每5±1周进行超声扫描至分娩,测量胎儿生长和胎儿胎盘血流,并使用有限混合模型推导腹围生长轨迹。
- 监测婴儿健康、生长和发育从出生至2岁,采集孕早期母亲血和脐静脉血进行非靶向代谢组学分析。
- 2012年2月8日至2019年11月30日纳入3598名孕妇并随访其婴儿至2岁。
主要发现
- 识别出四种超声推导的胎儿腹围生长轨迹:生长迟缓、早期加速生长、晚期加速生长和居中生长跟踪,在20-25周孕龄关键窗口内加速或减速。
- 这些不同表型在整个孕期具有匹配的胎儿胎盘血流模式,并在幼儿期呈现不同的生长、肥胖、视力和神经发育结局。
- 有709种母亲代谢物对生长迟缓表型具有正效应,54种对早期加速生长表型具有正效应;31种母亲代谢物对生长迟缓表型具有负效应,76种对早期加速生长表型具有负效应。
- 与生长迟缓表型相关的代谢物具有接近1.5的统计学显著比值比(提示胎儿生长受损代谢通路上调)。
- 代谢物与早期加速生长表型呈反向关系,具有接近0.6的统计学显著比值比(提示胎儿生长加速下调)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity predominantly affects populations in high-income countries and those countries facing epidemiological transition. The risk of childhood obesity is increased among infants who had overweight or obesity at birth, but in low-resource settings one in five infants are born small for gestational age. We aimed to study the relationships between: (1) maternal metabolite signatures; (2) fetal abdominal growth; and (3) postnatal growth, adiposity, and neurodevelopment. METHODS: In the prospective, multinational, observational INTERBIO-21st fetal study, conducted in maternity units in Pelotas (Brazil), Nairobi (Kenya), Karachi (Pakistan), Soweto (South Africa), Mae Sot (Thailand), and Oxford (UK), we enrolled women (≥18 years, with a BMI of less than 35 kg/m2, natural conception, and a singleton pregnancy) who initiated antenatal care before 14 weeks' gestation. Ultrasound scans were performed every 5±1 weeks until delivery to measure fetal growth and feto-placental blood flow, and we used finite mixture models to derive growth trajectories of abdominal circumference. The infants' health, growth, and development were monitored from birth to age 2 years. Early pregnancy maternal blood and umbilical cord venous blood samples were collected for untargeted metabolomic analysis. FINDINGS: From Feb 8, 2012, to Nov 30, 2019, we enrolled 3598 pregnant women and followed up their infants to 2 years of age. We identified four ultrasound-derived trajectories of fetal abdominal circumference growth that accelerated or decelerated within a crucial 20-25 week gestational age window: faltering growth, early accelerating growth, late accelerating growth, and median growth tracking. These distinct phenotypes had matching feto-placental blood flow patterns throughout pregnancy, and different growth, adiposity, vision, and neurodevelopment outcomes in early childhood. There were 709 maternal metabolites with positive effect for the faltering growth phenotype and 54 for the early accelerating growth phenotype; 31 maternal metabolites had a negative effect for the faltering growth phenotype and 76 for the early accelerating growth phenotype. Metabolites associated with the faltering growth phenotype had statistically significant odds ratios close to 1·5 (ie, suggesting upregulation of metabolic pathways of impaired fetal growth). The metabolites had a reciprocal relationship with the early accelerating growth phenotype, with statistically significant odds ratios close to 0.6 (ie, suggesting downregulation of fetal growth acceleration). The maternal metabolite signatures included 5-hydroxy-eicosatetraenoic acid, and 11 phosphatidylcholines linked to oxylipin or saturated fatty acid sidechains. The fungicide, chlorothalonil, was highly abundant in the early accelerating growth phenotype group. INTERPRETATION: Early pregnancy lipid biology associated with fetal abdominal growth trajectories is an indicator of patterns of growth, adiposity, vision, and neurodevelopment up to the age of 2 years. Our findings could contribute to the earlier identification of infants at risk of obesity. FUNDING: Bill & Melinda Gates Foundation.
引用
- Villar J, Ochieng R, Gunier RB, et al. Association between fetal abdominal growth trajectories, maternal metabolite signatures early in pregnancy, and childhood growth and adiposity: prospective observational multinational INTERBIO-21st fetal study. Lancet Diabetes Endocrinol. 2022. PMID: 36030799. doi:10.1016/S2213-8587(22)00215-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。